- Home
- IMOS vs AKBA Comparison
IMOS vs AKBA Comparison
Compare IMOS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMOS
- AKBA
- Stock Information
- Founded
- IMOS 1997
- AKBA 2007
- Country
- IMOS Taiwan
- AKBA United States
- Employees
- IMOS N/A
- AKBA N/A
- Industry
- IMOS Semiconductors
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- IMOS Technology
- AKBA Health Care
- Exchange
- IMOS Nasdaq
- AKBA Nasdaq
- Market Cap
- IMOS 895.7M
- AKBA 729.1M
- IPO Year
- IMOS N/A
- AKBA 2014
- Fundamental
- Price
- IMOS $30.77
- AKBA $1.66
- Analyst Decision
- IMOS
- AKBA Strong Buy
- Analyst Count
- IMOS 0
- AKBA 6
- Target Price
- IMOS N/A
- AKBA $6.25
- AVG Volume (30 Days)
- IMOS 19.4K
- AKBA 6.4M
- Earning Date
- IMOS 11-11-2025
- AKBA 11-10-2025
- Dividend Yield
- IMOS 2.09%
- AKBA N/A
- EPS Growth
- IMOS N/A
- AKBA N/A
- EPS
- IMOS 0.01
- AKBA N/A
- Revenue
- IMOS $748,307,671.00
- AKBA $225,071,000.00
- Revenue This Year
- IMOS $3.76
- AKBA $53.38
- Revenue Next Year
- IMOS $5.93
- AKBA $30.53
- P/E Ratio
- IMOS $145.13
- AKBA N/A
- Revenue Growth
- IMOS N/A
- AKBA 32.49
- 52 Week Low
- IMOS $12.78
- AKBA $1.52
- 52 Week High
- IMOS $30.98
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- IMOS 80.65
- AKBA 28.70
- Support Level
- IMOS $21.40
- AKBA $1.57
- Resistance Level
- IMOS $22.09
- AKBA $1.89
- Average True Range (ATR)
- IMOS 0.88
- AKBA 0.16
- MACD
- IMOS 0.78
- AKBA -0.06
- Stochastic Oscillator
- IMOS 97.74
- AKBA 5.94
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.